Kloosterboer H J, Benedek-Jaszmann L J, Kicovic P M
Organon Scientific Development Group, Oss, The Netherlands.
Maturitas. 1990 Apr;12(1):37-42. doi: 10.1016/0378-5122(90)90058-e.
The effects of 2.5 mg/day 7 alpha, 17 alpha-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14) on lipid metabolism, with particular reference to high-density lipoprotein (HDL)-related variables, were assessed in 14 healthy post-menopausal women after 12 and 36 mth of treatment. There were significant reductions in the following variables after both treatment periods: total phospholipids, total triglycerides, HDL-phospholipids and apolipoprotein A1. No changes were observed in total cholesterol or low-density lipoprotein (LDL) cholesterol over the entire treatment period. A significant but temporary decrease was observed in HDL-cholesterol after 12 mth, with a return to pretreatment values after 36 mth of treatment. The findings of this study clearly show that Org OD 14 has no adverse effects on the atherogenic variables, viz. LDL-cholesterol and triglycerides. Indeed, since the latter were lowered, its action is in fact beneficial. Moreover, its effect on HDL-cholesterol, the anti-atherogenic variable, is only temporary. We concluded from this study that although the composition of HDL changes during Org OD 14 treatment (especially as regards its cholesterol content), there is no evidence that reverse cholesterol transport is impaired.
在14名健康的绝经后女性中，评估了每天2.5毫克的7α,17α-17-羟基-7-甲基-19-去甲孕-5(10)-烯-20-炔-3-酮（Org OD 14）对脂质代谢的影响，特别关注与高密度脂蛋白（HDL）相关的变量，治疗12个月和36个月后进行评估。两个治疗期后，以下变量均有显著降低：总磷脂、总甘油三酯、HDL-磷脂和载脂蛋白A1。在整个治疗期间，总胆固醇或低密度脂蛋白（LDL）胆固醇未观察到变化。治疗12个月后，HDL胆固醇出现显著但短暂的下降，治疗36个月后恢复到治疗前水平。本研究结果清楚地表明，Org OD 14对致动脉粥样硬化变量，即LDL胆固醇和甘油三酯没有不良影响。事实上，由于后者降低了，其作用实际上是有益的。此外，其对HDL胆固醇（抗动脉粥样硬化变量）的影响只是暂时的。我们从这项研究得出结论，尽管在Org OD 14治疗期间HDL的组成发生了变化（特别是关于其胆固醇含量），但没有证据表明胆固醇逆向转运受损。
